Skip to main content

Market Overview

Regeneron/Sanofi Boast Positive Overall Survival Results In Late-Stage Cervical Cancer Study


Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed that they’re stopping a Phase 3 cervical cancer trial early after Libtayo showed cutting the risk of death by 31% over chemotherapy.

  • The Independent data monitoring committee unanimously recommended stopping the trial after reviewing the OS data at an interim analysis, thus paving the way for regulatory approval this year.
  • Among 608 participants, exactly half received Libtayo, and half got chemotherapy.
  • In the squamous cell carcinoma population, the median overall survival was 11.1 months for Libtayo compared to 8.8 months for chemo, translating to a hazard ratio of 0.73.
  • The smaller adenocarcinoma group saw better results, with a difference of 13.3 months versus 7.0 months leading to a hazard ratio of 0.56.
  • In the overall population, Libtayo was related to a median survival of 12.0 months compared to 8.5 months on chemo and a hazard ratio of 0.69.
  • The trial win comes on the heels of two FDA approvals that came within weeks of each other, one in basal cell carcinoma and another in advanced non-small cell lung cancer, expanding Libtayo’s label.
  • No new Libtayo safety signals were observed.
  • Price Action: REGN shares closed 0.3% higher at 471.46, and SNY shares closed 0.4% higher at $48.01 on Friday.

Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Posted-In: Cervical Cancer Phase 3 StudyBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at